RxDoctor Payments Data

Timothy Fisher, DO

Adult Medicine · Mc Minnville, TNNPI 1710920467

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 37.0% of the total. Reporting peaked in 2020 at $102 and has fallen 82.8% since, to $18 in 2024. That places this record below the midpoint for adult medicine clinicians in TN, where the typical reported total is $686.

$212in general payments, 2019–2025

Across 14 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$78
  • Lilly USA, LLC$55
  • AstraZeneca$27
  • Novo Nordisk$18
  • Integra Lifesciences Corporation$17
  • Johnson & Johnson$16

What the payments were for

  • Food & beverage$212100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$212 in reported general payments places this provider in the 25th percentile of 22 adult medicine providers in Tennessee.

See all adult medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$131,573
Medicare patients
176
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$82,936
OzempicSemaglutide61$60,061
TrulicityDulaglutide45$50,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$46,856
FarxigaDapagliflozin Propanediol56$42,791
XareltoRivaroxaban43$36,905
MounjaroTirzepatide29$36,438
Soliqua 100-33Insulin Glargine/Lixisenatide35$35,460
Teriparatide18$32,311
JardianceEmpagliflozin20$16,617
Breo ElliptaFluticasone/Vilanterol33$13,319
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$10,610
JanuviaSitagliptin Phosphate12$10,096
Bydureon BciseExenatide Microspheres12$9,961
VascepaIcosapent Ethyl22$6,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$55$86,44074 claims
Novo NordiskOzempic, Novolog$18$63,20976 claims
AstraZenecaFarxiga, Symbicort$27$48,26576 claims
Johnson & JohnsonXarelto$16$36,90543 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$78$35,46035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 22 adult medicine providers in Tennessee.

Other adult medicine in Mc Minnville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →